lysopadol 17.86 mg/ml oromucosal spray, solution
sanofi-aventis ireland limited t/a sanofi - ambroxol hydrochloride - oromucosal spray, solution - 17.86 milligram(s)/millilitre - anesthetics, local
pharmaton capsules
sanofi-aventis ireland limited t/a sanofi - panax ginseng extract; vitamin a; cholecalciferol concentrate ; all-rac-alpha tocopheryl acetate; ascorbic acid; thiamine nitrate; riboflavin; nicotinamide; pyridoxine hydrochloride; folic acid; cyanocobalamin; biotin; anhydrous dibasic calcium phosphate; iron (as dried ferrous sulphate); magnesium sulfate dried; zinc (as zinc sulphate monohydrate); copper (as dried copper sulpahte); selenium (as sodium selenate); lecithin - capsule, soft - n/a - other combinations of nutrients
dioralyte rebalance blackcurrant powder for oral solution
sanofi-aventis ireland limited t/a sanofi - sodium chloride ; potassium chloride; glucose; disodium hydrogen citrate - powder for oral solution - 0.47/0.30/3.56/0.53 gram(s) - oral rehydration salt formulations
dioralyte rebalance citrus powder for oral solution
sanofi-aventis ireland limited t/a sanofi - sodium chloride ; potassium chloride; glucose; disodium hydrogen citrate - powder for oral solution - 0.47/0.30/3.56/0.53 gram(s) - oral rehydration salt formulations
dioralyte rebalance natural powder for oral solution
sanofi-aventis ireland limited t/a sanofi - sodium chloride ; potassium chloride; glucose; disodium hydrogen citrate - powder for oral solution - 0.47/0.30/3.56/0.53 gram(s) - oral rehydration salt formulations
acomplia
sanofi-aventis - rimonabant - obesity - antiobesity preparations, excl. diet products - as an adjunct to diet and exercise for the treatment of obese patients (bmi 30 kg/m2), or overweight patients (bmi 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).
zimulti
sanofi-aventis - rimonabant - obesity - antiobesity preparations, excl. diet products - as an adjunct to diet and exercise for the treatment of obese patients (bmi 30 kg/m2), or overweight patients (bmi 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).
amaryl 1 mg tablet
sanofi-aventis ireland limited t/a sanofi - glimepiride - tablet - 1.0 milligram(s) - sulfonamides, urea derivatives; glimepiride
amaryl 3 mg tablet
sanofi-aventis ireland limited t/a sanofi - glimepiride - tablet - 3 milligram(s) - sulfonamides, urea derivatives; glimepiride
latanoprost/timolol zentiva 50mcg/ml + 5 mg/ml eye drops solution
sanofi-aventis ireland limited t/a sanofi - latanoprost, timolol maleate - eye drops solution - 50mcg/ml + 5 mg/ml - beta blocking agents